Is Genelux Corporation Common Stock (GNLX) overvalued? · rev $8.0K
Genelux Corporation Common Stock (GNLX) is a biotechnology company listed on US.
This page asks whether Genelux Corporation Common Stock (GNLX) looks expensive on cached numbers — not a short thesis.
Latest reported GNLX revenue for 2025-12-31 was $8.0K. Net income was -$32.1M. Revenue was up 0.0% from 2024-12-31 to 2025-12-31. GNLX currently screens at market cap $130.6M.
GNLX currently screens at market cap $130.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GNLX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GNLX stock page for the full model, not this heading.
Not investment advice.